...
首页> 外文期刊>AMERICAN JOURNAL OF HEMATOLOGY >Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia?
【24h】

Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia?

机译:提高PF4 ELISA诊断肝素诱导的血小板减少的特异性?

获取原文
获取原文并翻译 | 示例
           

摘要

Heparin induced thrombocytopenia (HIT) is a serious complication of heparin therapy. The PF4 ELISA is a serologic assay that provides laboratory support for the clinical diagnosis of HIT, but it is often positive in patients who do not have the syndrome. We examined whether the specificity of the PF4 ELISA can be improved by 1) taking antibody potency into consideration, 2) by measuring only IgG antibodies, and 3) by utilizing a high concentration heparin inhibition step. We reviewed clinical information on 116 patients whose samples were referred for HIT antibody testing and assigned each a clinical score related to the likelihood of the patient having HIT. The scores were then correlated with serologic findings. Patients with strongly positive PF4ELISA results (OD ≥ 1.0) using both versions of the assay (IgG/A/M and IgG only) had clinical scores and SRA activity that were significantly higher than those having reactive or negative results. When the IgG-only PF4 ELISA was used, only the strongly positive result group had significantly higher clinical scores and SRA release, and fewer samples were classified as weakly positive or reactive, suggesting that detection of IgG only in the PF4 ELISA improves the assay's specificity. The heparin inhibition step identified “reactive” samples that were associated with clinical scores and SRA release indistinguishable from the “negative” result groups, confirming that this step further improves specificity of the test. This study supports utilizing these 3 modifications of the PF4 ELISA to improve specificity in supporting the clinical diagnosis of HIT. Am. J. Hematol., 2012. ? 2012 Wiley Periodicals, Inc.
机译:肝素诱导的血小板减少症(HIT)是肝素治疗的严重并发症。 PF4 ELISA是一种血清学检测方法,可为HIT的临床诊断提供实验室支持,但对于没有该综合征的患者通常是阳性的。我们检查了以下因素是否可以提高PF4 ELISA的特异性:1)考虑抗体效力; 2)仅测量IgG抗体; 3)利用高浓度肝素抑制步骤。我们审查了116名患者的临床信息,这些患者的样本被送至HIT抗体测试,并为每位患者分配了与HIT患者可能性相关的临床评分。然后将分数与血清学发现相关联。使用两种检测方法(仅IgG / A / M和IgG)的PF4ELISA结果均为强阳性(OD≥1.0)的患者,其临床评分和SRA活性均显着高于具有反应性或阴性结果的患者。当使用仅IgG的PF4 ELISA时,只有强阳性结果组的临床评分和SRA释放显着较高,并且分类为弱阳性或反应性的样品较少,这表明仅在PF4 ELISA中检测IgG可以提高测定的特异性。肝素抑制步骤确定了与临床评分相关的“反应性”样品,SRA释放与“阴性”结果组没有区别,证实了该步骤进一步提高了测试的特异性。这项研究支持利用PF4 ELISA的这3种修饰来提高特异性,以支持HIT的临床诊断。上午。 J.血友病杂志,2012年。 2012 Wiley期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号